Author + information
- Received December 20, 2019
- Revision received April 2, 2020
- Accepted April 6, 2020
- Published online June 22, 2020.
- Yanping Cheng, MDa,
- Marco Ferrone, MDa,
- Qing Wang, MD, PhDb,
- Laura E.L. Perkins, DVM, PhDb,
- Jennifer McGregor, BSa,
- Björn Redfors, MD, PhDa,
- Zhipeng Zhou, MAa,
- Richard Rapoza, PhDb,
- Gerard B. Conditt, RCISa,
- Aloke Finn, MDc,
- Renu Virmani, MDc,
- Grzegorz L. Kaluza, MD, PhDa and
- Juan F. Granada, MDa,∗ ()
- aCRF Skirball Center for Innovation, Orangeburg, New York
- bAbbott Vascular, Santa Clara, California
- cCVPath Institute, Inc., Gaithersburg, Maryland
- ↵∗Address for correspondence:
Dr. Juan F. Granada, CRF Skirball Center for Innovation, Cardiovascular Research Foundation, 8 Corporate Drive, Orangeburg, New York 10962.
• The bioresorption process of the Absorb BVS has been directly characterized only in a normal swine model and indirectly (by imaging surrogates) in clinical studies.
• Using multimodality imaging and histology, this study indicates that in a diseased animal model, the resorption and integration of BVS into the arterial wall is not affected by the presence of untreated hyperlipidemia and atherosclerosis progression.
• Imaging and histology suggest that BVS degradation progresses similarly in the presence of atherosclerosis compared with earlier data from nonatherosclerotic arteries. However, BVS is not immune to the development of neoatherosclerosis.
The integration of the Absorb bioresorbable vascular scaffold (BVS) into the arterial wall has never been tested in an in vivo model of atherosclerosis. This study aimed to compare the long-term (up to 4 years) vascular healing responses of BVS to an everolimus-eluting metallic stent in the familial hypercholesterolemic swine model of atherosclerosis. The multimodality imaging and histology approaches indicate that the resorption and vascular integration profile of BVS is not affected by the presence of atherosclerosis. BVS demonstrated comparable long-term vascular healing and anti-restenotic efficacy to everolimus-eluting metallic stent but resulted in lower late lumen loss at 4 years.
- bioresorbable vascular scaffolds
- familial hypercholesterolemic swine
- metallic drug-eluting stents
This study was sponsored by Abbott Vascular, Santa Clara, California. Dr. Wang is an employee of Abbott Laboratories. Dr. Perkins is an employee of and shareholder in Abbott Laboratories. Dr. Rapoza is an employee of Abbott Laboratories. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received December 20, 2019.
- Revision received April 2, 2020.
- Accepted April 6, 2020.
- 2020 The Authors